|Chemical and physical data|
|Molar mass||334.329 g/mol g·mol−1|
|3D model (JSmol)|
Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.
- Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer's Disease" (PDF). The Open Neuropsychopharmacology Journal. 1: 19–23.
- Pogacic, Vanda; Herling, Paul (2007). "List of Drugs in Development for Neurodegenerative Diseases". Neurodegenerative Diseases. 4 (6): 443486. doi:10.1159/000107705. ISSN 1660-2862.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|